MedTrace Logo

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

NCT01213160 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-06-29

No results posted yet for this study

Summary

The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.

Conditions

  • Cancer
  • Advanced Solid Malignancies

Interventions

DRUG

AZD4547

film coated tablet, PO, twice daily

Sponsors & Collaborators

Principal Investigators

  • Paul Stockman · AstraZeneca

  • Hideo Saka, MD, PhD · National Hospital Organisation Nagoya Medical Centre

  • Yasuo Takahashi, MD · National Hospital OrganisationHokkaido Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
150 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213160 on ClinicalTrials.gov